DGAP-News: AiCuris Anti-infective Cures AG / Tag(s): Miscellaneous
AiCuris Names Madam Therapeutics with its Innovative Peptide Approach to Combat Antibiotic Resistance as First Winner of 2022 AiCubator Resident Status
08.04.2022 / 09:00
The issuer/publisher is responsible for the content of the notification.
AiCuris Names Madam Therapeutics with its Innovative Peptide Approach to Combat Antibiotic Resistance as the First Winner of AiCubator 2022 Resident Status, an Initiative to Support New Innovative Projects, at BIOCOM AMR 2022 Conference
- In the second year of the AiCubator initiative, an innovative artificial intelligence-based approach by Madam Therapeutics to combat antimicrobial resistance using dual-action peptides (antimicrobial and anti-biofilm) was nominated as the first new participant in 2022
- The “AiCubator” was launched by AiCuris in mid-2020 to provide long-term support for early but promising anti-infective research projectsmake sure
Wuppertal, Germany, April 8, 2022 – AiCuris Anti-infective Cures AG, a leader in the discovery and development of drugs to treat infectious diseases, today announced the first winner of the 2022 AiCuris AiCubator Initiative, the second round of the “Accelerator” program of the society. Projects submitted in the field of anti-infective research were evaluated by AiCuri experts based on a wide variety of criteria. This includes status of target identification, preliminary efficacy data, indication treated, and potential competitive advantages over existing treatment standards. Over a period of up to three years, winning projects will benefit from scientific support, preclinical and clinical development experience, and industry insights from AiCuris to advance their ideas and approaches.
“We are very excited to welcome the first 2022 AiCubator Resident Status winner,” said doctor Holger Zimmermann, CEO of AiCuris Anti-infective Cures AG. “Exceptional and innovative approaches are urgently needed to address today’s public health challenges and fight antimicrobial resistance and complex infections. The AiCubator program was created to find and fund such projects – from projects that support the development of an innovative drug based on new scientific approaches.”
“The good experiences of the first year of the AiCubator initiative encourage us to continue supporting promising early-stage projects based on new scientific principles and ideas. With this, we aim to fill gaps in the pipeline, fight antimicrobial resistance and prevent future pandemics,” he added. “We look forward to working with the designated project team and helping move Madam Therapeutics’ project into the next stage of development.”
The project: Artificial intelligence and a unique peptide approach to combat complex bacterial infections
Madam Therapeutics, a biotechnology company from Oss in the Netherlands, has built an extensive library of selective dual-action peptides called “synthetic antimicrobial and antibiofilm peptides” (SAAPs). These peptides are highly effective in killing multi-resistant pathogens under physiologically harsh conditions without inducing resistance. In addition, SAAPs eliminate biofilms formed by bacteria to protect against the human immune system and antibiotics. Through the use of artificial intelligence, the company identifies the most suitable SAAP variants in order to develop drug candidates targeted against different antibiotic-resistant bacteria in various indications. Madam Therapeutics has a preclinical live Proof of Efficacy (Proof of Concept, POC) in artificial wound infections, implant infections, as well as lung and bladder infections. SAAPs have been shown to outperform many known antimicrobial peptides (AMPs) that are in preclinical and clinical stages. The first targeted therapeutic indications are diabetic foot infections and sepsis.
“We are excited to join the AiCubator program and benefit from AiCuris’ extensive experience in developing anti-infectives,” said Remko van Leeuwen, CEO of Madam Therapeutics. “Both companies are committed to combating antimicrobial resistance and, with the support of AiCuris, we hope to accelerate the realization of the next steps in the further development of our dual-action SAAPs, a new generation of antibiotics breaking resistance.
To support early ideas that could lead to the next resistance-busting antibiotic or anti-infective, AiCuris has begun selecting promising research projects for AiCubator, the company’s innovative funding program. The AiCubator initiative is aimed at academic research groups or newly established biotech start-ups with anti-infective projects in important research areas at an early stage of development that are scientifically interesting but not yet mature enough to be licensed . The program is designed to help scientists and startups build their own business and scale the underlying ideas and approaches to advanced status. AiCubator program participants receive long-term support, including scientific and regulatory advice and business development support. Also, they get an insight into preclinical and clinical drug research and the pharmaceutical industry.
You can find more information about AiCubator here: www.aicuris.com/AiCubator.
About AiCuris Anti-infective Cures AG
AiCuris was founded in 2006 as a spin-off from Bayer AG and focuses on the research and development of active ingredients against infectious diseases. The main investors in the company are Drs. Strüngmann. With PREVYMIS(TM) (letermovir), a non-nucleoside cytomegalovirus (CMV) inhibitor has been developed that exerts its effect via a novel mode of action. It was licensed to MSD in 2012 and received marketing approval in the EU, US, Japan and other parts of the world for the prevention of CMV infection in adult recipients allogeneic hematopoietic stem cells (HSCGs). The company is developing other drugs against viruses such as herpes simplex virus (HSV), hepatitis B virus (HBV), adenoviruses, as well as against SARS-CoV-2 and others. virus with pandemic potential. In 2022, AiCuris acquired the exclusive rights to develop and commercialize direct-acting RNA-based therapies for the prevention of severe BK virus (BKV) infection in immunocompromised patients. In the area of antibacterial agents, AiCuris is focused on finding innovative treatment options for indications with high unmet medical needs, such as life-threatening (multi-)drug resistant hospital pathogens. In 2019, AiCuris partnered with Lysando to advance the fight against antimicrobial resistance with innovative approaches based on Lysando’s Artilysin(R) technology platform. Artilysin(R)s are a new class of engineered molecules derived from phage lysine with a new mode of action and the potential to replace conventional antibiotics. In 2021, AiCuris expanded its collaboration with Lysando with a focus on diabetic foot infections.
In November 2018, Dr. Holger Zimmermann and Prof. Dr. Helga Rübsamen-Schaeff (founder and CEO of AiCuris) received the German Future Prize 2018 for the development of Letermovir and his project “Protection in the absence of a immune system – the vital innovation against dangerous viruses”.
For more information about the company, visit www.aicuris.com
Follow us on LinkedIn.
|Company details :
AiCuris Anti-Infectious Cures SA
MC Services Ltd.
|Igor Orshanskiy, PhD
Telephone: +49 202 317 63 0
04/08/2022 Publication of a Corporate News/Financial News, transmitted by the DGAP – a service of EQS Group AG.
The issuer/publisher is responsible for the content of the notification.
DGAP’s distribution services include statutory reports, institutional/financial news and press releases.
Media archive at http://www.dgap.de